The Emicenter diagnostic excellence center in Casavatore is embracing the latest innovations in cancer prevention with the launch of a study using Mistral, the medical device developed by Predict for breath sampling.
Initially used to support prostate cancer screening, the Mistral project is expanding its scope at the diagnostic center: as of July 2025, it is also being used in studies on breast and lung cancers, confirming the high potential of breath analysis as a tool for the medicine of the future.
Thanks to artificial intelligence and the identification of volatile organic compounds (VOCs) present in human breath, Mistral enables the creation of a unique metabolic fingerprint for each individual. This approach makes it possible to detect physiopathological changes potentially linked to oncological diseases, with the goal of enabling earlier intervention.
The collaboration between Predict and Emina stems from a shared commitment to bringing cutting-edge, accessible, and non-invasive solutions to local communities. The involvement of a highly qualified center like Casavatore is a crucial step in the clinical validation of the Mistral project and its path toward large-scale implementation.
The extension of the study to breast and lung cancers reflects the project’s ambition: to make a concrete contribution to transforming early screening strategies by offering reliable, rapid tools focused on improving patients’ quality of life.
